MERFX | MERIX | MERFX / MERIX | |
Total Expense Ratio | 1.56 | 1.27 | 123% |
Annual Report Gross Expense Ratio | 1.67 | 1.37 | 122% |
Fund Existence | 37 years | 12 years | - |
Gain YTD | 5.834 | 6.028 | 97% |
Front Load | 6% | N/A | - |
Min. Initial Investment | 2500 | 100000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 2.39B | 2.39B | 100% |
Annual Yield % from dividends | 1.65 | 2.10 | 78% |
Returns for 1 year | 5.24 | 5.48 | 96% |
Returns for 3 years | 9.20 | 10.12 | 91% |
Returns for 5 years | 10.48 | 12.01 | 87% |
Returns for 10 years | 24.85 | 27.89 | 89% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SHPAX | 19.00 | 0.15 | +0.80% |
Saratoga Health & Biotechnology A | |||
FCUPX | 20.43 | 0.04 | +0.20% |
NYLI PineStone U.S. Equity Class P | |||
TWSIX | 137.74 | -0.45 | -0.33% |
American Century Select I | |||
MUESX | 36.20 | -0.13 | -0.36% |
MFS Blended Research Core Equity R2 | |||
FMEFX | 42.59 | -0.16 | -0.37% |
Nuveen Small/Mid Cap Growth Opp R6 |